Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

oduct liability, supply, competition and other risks).

-more-

(Financial Table Attached)

ENTREMED, INC.

SUMMARY OF OPERATING RESULTS

Three Months Ended

September 30,

2008 2007

Total revenues $3,501,307 $3,520,259

Research and development 4,957,067 5,109,257

General and administrative 1,551,900 1,706,451

Acquired in-process research and development 0 0

Net Loss (3,397,877) (3,035,346)

Net Loss per share (basic and diluted)

attributable to common shareholders $(0.04) $(0.04)

Weighted average number of shares

outstanding (basic and diluted) 87,728,644 84,223,912

Nine Months Ended

September 30,

2008 2007

Total revenues $3,501,307 $3,520,259

Research and development 16,629,127 18,089,240

General and administrative 5,274,585 5,407,588

Acquired in-process research and development 2,000,000 0

Net Loss (21,314,476) (18,643,625)

Net Loss per share (basic)

attributable to common shareholders $(0.26) $(0.23)

Weighted average number of shares

outstanding (basic) 86,060,438 84,015,999

Ca
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... CHICAGO , Aug. 1. 2014 As ... U.S., the 2014 AACC Annual Meeting & Clinical Lab ... testing and patient care are introduced to the healthcare ... by the Expo,s 650 exhibitors will include the latest ... Advances in smartphones and biosensors have enabled ...
(Date:8/1/2014)... 2014 The  PROPEL Center  of the  iBIO ... rate of early-stage life sciences companies in ... 15 grants to help Illinois ...   in Chicago .   AdvaMed ... North America , bringing more than 1,000 ...
(Date:8/1/2014)... Once a decision has been made to increase ... how to define your tolerance for lowest cost design ... Director of Facilities Integration at Fluor Industrial Services, Craig ... and special guest Carrier Li, Director in Global Asset ... provide an examination of the Conceptual Design process and ...
(Date:8/1/2014)... Glencoe Software, Inc. is pleased ... ( http://glencoesoftware.com/data-inpress.html ), a suite of data ... into on-line publications.  The suite comprises Glencoe ... Photo - http://photos.prnewswire.com/prnh/20140731/132410   ... The DataViewer is a browser-based ...
Breaking Biology Technology:Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Glencoe Software Launches Data InPress 2Glencoe Software Launches Data InPress 3
... (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ... virus (HCV) infection, today announced that it will release ... 2008 on March 11,2008 at 7:00 a.m. EDT and ... results at 11:30 a.m. EDT on the same day., ...
... (Nasdaq,CM: INSM), a developer of follow-on biologics and biopharmaceuticals, today,reported results for ... and Recent Company Highlights, -- Follow-on Biologics Program ... Factor or G-CSF) ... products to enter clinical trials in 2008; ...
... Vical Incorporated,(Nasdaq: VICL ) today announced ... Officer, will participate in a roundtable discussion,"An Industry ... in,Global Health Product Development," and present an overview ... on Tuesday,March 11, at the Biotechnology Industry Organization ...
Cached Biology Technology:Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 3Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 4Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 5Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 6Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 7Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 8Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 9Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 10Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results 11Vical to Present at BIO and BVGH Global Health Partnering Event 2Vical to Present at BIO and BVGH Global Health Partnering Event 3
(Date:7/31/2014)... beneath many of the roughly 156,000 gas stations ... corrosion in parts of underground gas storage tankscorrosion ... of groundwater, a source of drinking water. In ... reported many rapidly corroding gas storage tank components ... associated with use of gasoline-ethanol blends and the ...
(Date:7/31/2014)... protected 100 percent of animal models against the highly ... causes an intestinal disease that kills approximately 30,000 Americans ... Infection and Immunity . , In the ... against the purified toxins produced by C. difficile ... a laboratory model that mimics the human disease, after ...
(Date:7/31/2014)... An important step has been made to help better identify ... both an abnormal narrowing and enlarging of medium sized arteries ... kidneys and other organs causing damage. In a new report ... Journal , scientists provide evidence that that FMD may ... addition, they show a connection to abnormalities of bones and ...
Breaking Biology News(10 mins):NIST corrosion lab tests suggest need for underground gas tank retrofits 2C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... A method to detect contaminants in municipal water supplies ... Laboratory researchers whose findings are published on line in ... demonstrates that the technology that uses algae as sentinels ... Miguel Rodriguez Jr. and Elias Greenbaum of the Department ...
... Calif., August 27, 2009 -- Researchers at Burnham ... Southwestern Medical Center and University of Maryland have ... many bacteria can be targeted to kill dangerous ... can inhibit this enzyme and suppress the growth ...
... A new candidate gene for Specific Language Impairment has ... Rice at the University of Kansas, in collaboration with ... Gayn of Neocodex, Seville, Spain. The finding, reported in ... Disorders , was discovered by examining genes previously identified ...
Cached Biology News:ORNL scientists hone technique to safeguard water supplies 2The path to new antibiotics 2Researchers report gene associated with language, speech and reading disorders 2
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... Immunogen: Goats were immunized ... Antibody was isolated by affinity chromatography using ... anti- human T7 affinity purified antibodies were ... method. Specificity: Antibody ...
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
Biology Products: